StoxLaurus Labs vs Zydus Lifesciences: share price & financials comparison
NSE: LAURUSLABS vs ZYDUSLIFE · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Laurus Labs vs Zydus Lifesciences at a glance
Laurus Labs (LAURUSLABS) has a market capitalisation of ₹1,26,430 Cr, against ₹1,19,550 Cr for Zydus Lifesciences (ZYDUSLIFE). Over the past year Laurus Labs has returned +143.3%, compared with +19.4% for Zydus Lifesciences. On valuation, Zydus Lifesciences trades at a lower P/E of 28.6 versus 94.4. Laurus Labs earns a higher return on equity (22.1% vs 15.0%). Laurus Labs comes out ahead on profitability, growth, financial health, momentum and technicals. Zydus Lifesciences comes out ahead on size and valuation. Across the scored metrics below, Laurus Labs leads on 12 and Zydus Lifesciences on 5. On StoxGud's 10-point checklist, Laurus Labs scores 8/10 and Zydus Lifesciences scores 10/10.
| Metric | Laurus Labs | Zydus Lifesciences |
|---|---|---|
| Size | ||
| Market cap | ₹1,26,430 Cr | ₹1,19,550 Cr |
| Revenue (latest FY) | ₹6,813 Cr | ₹27,148 Cr |
| Net profit (latest FY) | ₹889 Cr | ₹5,040 Cr |
| Valuation | ||
| P/E | 94.4 | 28.6 |
| P/B | 20.86 | 4.30 |
| Dividend yield | 0.07% | 0.93% |
| Profitability | ||
| Return on equity | 22.1% | 15.0% |
| Net profit margin | 17.1% | 13.8% |
| Operating margin | 30.4% | 27.0% |
| Growth | ||
| Revenue growth (YoY) | +33.4% | +29.2% |
| Net profit growth (YoY) | +126.4% | -26.5% |
| Revenue CAGR (multi-year) | +7.2% | +12.4% |
| Financial health | ||
| Debt to equity | 0.41 | 0.48 |
| Momentum | ||
| 1-month return | +14.0% | +3.9% |
| 1-year return | +143.3% | +19.4% |
| 3-year CAGR | +84.5% | +27.0% |
| 5-year CAGR | +36.4% | +19.4% |
| 10-year CAGR | — | +12.1% |
| Distance from 52W high | -2.7% | -3.8% |
| Technicals | ||
| RSI (14) | 71 | 67 |
| Price vs 200-day avg | +58.0% | +15.1% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Laurus Labs | Zydus Lifesciences |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 8/10 | 10/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Laurus Labs or Zydus Lifesciences?
Laurus Labs has a market cap of ₹1,26,430 Cr and Zydus Lifesciences has a market cap of ₹1,19,550 Cr as of 06 Nov 2026.
Which has a lower P/E, Laurus Labs or Zydus Lifesciences?
Zydus Lifesciences has the lower P/E: Laurus Labs trades at 94.4 and Zydus Lifesciences at 28.6.
Which gave better returns in the last year, Laurus Labs or Zydus Lifesciences?
Laurus Labs did better: Laurus Labs returned +143.3% and Zydus Lifesciences returned +19.4% over one year.
Is Laurus Labs or Zydus Lifesciences a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Laurus Labs scores 8/10 and Zydus Lifesciences scores 10/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.